PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nadofaragene Firadenovec→

Nadofaragene Firadenovec PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1823059-12-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Non-replicating adenoviral vector gene therapy delivering interferon alfa-2b
Mechanism of action
An adenoviral vector delivers the human IFNα2b gene to bladder urothelial cells. Transduced cells express interferon alfa-2b locally, promoting antitumour immune responses and growth-inhibitory effects within the bladder.
Indications / reported uses
  • Treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumours; for intravesical use only

Sources: NLM DailyMed — ADSTILADRIN, updated 24 March 2026 · FDA — ADSTILADRIN product information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nadofaragene Firadenovec PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nadofaragene Firadenovec Permitted Daily Exposure (PDE) report (the Nadofaragene Firadenovec PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nadofaragene Firadenovec Occupational Exposure Limit (OEL) report (the Nadofaragene Firadenovec OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.